title: Biologics in systemic sclerosis.
abstract: Systemic sclerosis (scleroderma) is a heterogeneous autoimmune disorder characterized by collagen overproduction that leads to cutaneous and internal organs sclerosis and pulmonary arterial hypertension. SSc has high morbidity and mortality. SSc pathogenesis is uncertain. At present most therapies of SSc are symptomatic. Effective therapeutic approaches are lacking. Accompanying a growing understanding of SSc pathogenesis, various key mediators are being evaluated as the therapeutic targets. This review described the effects of these key mediators in SSc.
authors.forename: Jingxiu
authors.initials: J
authors.lastname: Xuan
authors.forename: Long
authors.initials: L
authors.lastname: Shen
authors.forename: Chongjie
authors.initials: C
authors.lastname: Zhang
authors.affiliation: Department of Medicinal Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Address: 17 Renming Street South, 3rd Section, Chengdu, Sichuan, China 610041. cjzhang49@hotmail.com.
authors.forename: Julian L
authors.initials: JL
authors.lastname: Ambrus
mesh_terms: D000818:Animals; D001688:Biological Products / Q000627:therapeutic use*; D016207:Cytokines / Q000276:immunology; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology
chemical_list: D001688:Biological Products; D016207:Cytokines; D010982:Platelet-Derived Growth Factor; D017479:Receptors, Platelet-Derived Growth Factor